Gossamer Bio said Tuesday that its experimental drug for pulmonary arterial hypertension achieved the main goal of a mid-stage clinical trial. But the treatment effect was smaller than expected, raising concerns that the drug may not be potent enough to provide a meaningful benefit for patients.
Shares of Gossamer fell 64% to $3 in early trading.
Pulmonary arterial hypertension, or PAH, is a chronic, progressive condition in which high blood pressure in the arteries of the lungs leads to difficulty breathing and walking.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect